%0 Journal Article
%T Advance of theragnosis biomarkers in lung cancer: from clinical to molecular pathology and biology
%A Anna Kron
%A Anne Maria Schultheis
%A Carina Heydt
%A Christina Alidousty
%A Juergen Wolf
%A Reinhard Buettner
%A Svenja Wagener-Ryczek
%A Till Baar
%J SCIE-indexed Journal
%D 2019
%R 10.21037/jtd.2018.12.03
%X Lung cancer is the leading cause of cancer deaths in men and women worldwide (1). Historically, it was divided in two major groups¡ªsmall cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) with 80% to 85% of cases belonging to the latter group (2). Over the last years, however, the advent of next-generation sequencing (NGS) technologies and sequencing studies revealed that this classification is outdated and that particularly the term ¡°non-small cell lung cancer¡± involves an extremely heterogeneous set of diseases at the molecular level that translates into both, tumors¡¯ clinical behavior and therapeutic decision-making (3)
%U http://jtd.amegroups.com/article/view/25843/html